Phase II VIRO-15 trial of olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)

R.W Holloway,A.A Mendivil,J.E Kendrick,L.N Abaid,J.V Brown,C.K Fitzsimmons,J.A Kennard,M.M King,J Leblanc,K Lopez,M Manyam,N.D Mckenzie,K.M Mori,J.L Smith,A.J Stephens,S Ahmad

doi:10.1016/j.ygyno.2020.06.126

Phase II VIRO-15 trial of olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)

R.W Holloway, A.A Mendivil + Show 14 more

https://doi.org/10.1016/j.ygyno.2020.06.126

Copy DOI

Journal: Gynecologic Oncology	Publication Date: Oct 1, 2020
Citations: 1

Affiliation: Florida Hospital Cancer Institute, Gynecologic Oncology Associates

#Platinum-resistant/refractory Ovarian Cancer #Carboplatin-doublet + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: A previous phase 1b trial with Olvi-Vec oncolytic viral immunotherapy (OVI) in platinum-resistant/refractory ovarian cancer (PRROC) established the recommended phase 2 dose of 3 × 109 pfu/day by intraperitoneal route. This trial evaluated the efficacy of OVI followed by carboplatin-doublet (CD) with and without bevacizumab (BEV) in PRROC.

Full Text